Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease

Journal of Clinical Rheumatology

Volumn 20, Issue 7, 2014, Pages 379-382

  Bhavsar, Sankalp Virendrakumar ^a   Carmona, Raj ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti RNA polymerase III; Renal crisis; Scleroderma; Systemic sclerosis; TTP HUS

Indexed keywords

ANTINUCLEAR ANTIBODY; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; HYDROXYCHLOROQUINE; NIFEDIPINE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; RNA ANTIBODY; RNA POLYMERASE III ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; DNA DIRECTED RNA POLYMERASE III;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; CASE REPORT; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FOOT PAIN; GASTROESOPHAGEAL REFLUX; GLOMERULUS CAPILLARY; HAND PAIN; HEMODIALYSIS; HUMAN; IMMUNE COMPLEX NEPHRITIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KNEE; LABORATORY TEST; LYMPHOCYTOPENIA; METACARPOPHALANGEAL JOINT; MIDDLE AGED; PERICARDIAL EFFUSION; PERITONEAL DIALYSIS; PHYSICAL EXAMINATION; PLASMAPHERESIS; POLYARTHRITIS; PROXIMAL INTERPHALANGEAL JOINT; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA; SCLERODERMA RENAL CRISIS; SKIN DISEASE; SKINFOLD THICKNESS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULCER; URINALYSIS; ACUTE KIDNEY INJURY; BLOOD; COMPLICATION; IMMUNOLOGY; SCLERODERMA, SYSTEMIC;

ACUTE KIDNEY INJURY; ADULT; ANTIBODIES; FEMALE; HUMANS; MIDDLE AGED; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 84916206379     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000167     Document Type: Article

References (14)

1. Shanmugam VK, Steen VD. Renal disease in scleroderma: An update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 2012;24: 669-676.
2. Molina JF, Anaya JM, Cabrera GE, et al. Systemic sclerosis sine scleroderma: An unusual presentation in scleroderma renal crisis. J Rheumatol 1995;22: 557-560.
3. Phan TG, Cass A, Gillin A, et al. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma. J Rheumatol 1999;26: 2489-2492.
4. Horn HC, Ottosen P, Junker P. Renal crisis in asclerodermic scleroderma-lupus overlap syndrome. Lupus 2001;10: 886-888.
5. Leroy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28: 1573-1576.
6. Guillevin L, Bérezné A, Seror R, et al. Scleroderma renal crisis: A retrospective multicenter study on 91 patients and 427 controls. Rheumatology 2012;51: 460-467.
7. Batal I, Domsic RT, Medsger TA, et al. Scleroderma renal crisis: A pathology perspective. Int J Rheumatol 2010;2010: 543704.
8. Steen V, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41: 1613-1619.
9. Mouthon L, Bussone G, Berezné A, et al. Scleroderma renal crisis. J Rheumatol 2014;41: 1040-1048.
10. Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: A cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011;13: R211.
11. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181.
12. Hudson M, Baron M, Tatibouet S, et al. International scleroderma renal crisis study investigators. Semin Arthritis Rheum 2014;43: 666-672.
13. Steen V, Costantino J, Shapiro A, et al. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113: 352-357.
14. Steen VD, Medsger TA Jr. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66: 940-944.